According to the Zhitong Finance App, Huaren Pharmaceutical (300110.SZ) announced its 2023 results, with operating income of 1,636 billion yuan, up 1.04% year on year; net profit attributable to shareholders of listed companies was 188 million yuan, up 4.03% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 166 million yuan, up 14.27% year on year; basic income per share was 0.159 yuan/share, and plans to distribute a cash dividend of 0.21 yuan (tax included) to all shareholders for every 10 shares.